Effect of multimorbidity on hypertension management.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 10 2023
31 10 2023
Historique:
received:
12
04
2023
accepted:
12
10
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Multimorbidity, the coexistence of multiple health conditions, is associated with functional decline, disability, and mortality. We aimed to investigate the effects of multimorbidity on hypertension treatment and control rates by analyzing data from the Korean National Health and Nutrition Examination Survey database, which is a cross-sectional, nationally representative survey conducted by the Korean government. Multimorbidity, defined as having two or more chronic diseases, was evaluated by blood pressure measurements, blood chemistry examinations, and questionnaires. We classified the participants according to the number of multimorbidities from 0 to ≥ 6. Association analysis was performed to identify the patterns of multimorbidity related to hypertension control. From 2016 to 2020, 30,271 adults (≥ 20 years) were included in the analysis (age: 52.1 ± 16.8 years, male: 44.0%), and 14,278 (47.2%) had multimorbidity. The number of chronic conditions was significantly higher in older adults, women, and hypertensive patients. Multimorbidity was associated with hypertension treatment. The number of chronic conditions was significantly higher in controlled compared to uncontrolled patients (3.6 ± 1.7 vs 2.9 ± 1.6, p < 0.001). But the control rate of hypertension among treated patients was lower in patients with multimorbidity (75.6% in hypertension only group vs 71.8% in multimorbidity group, p = 0.009). Multimorbidity patterns showed distinct features in treated and controlled hypertensive patients. In conclusion, multimorbidity has a beneficial effect on the treatment of hypertension, but the control rate of systolic blood pressure was lower among the patients with multimorbidity. More attention should be paid to the hypertensive patients with multimorbidity to improve the control rate of hypertension.
Identifiants
pubmed: 37907571
doi: 10.1038/s41598-023-44813-0
pii: 10.1038/s41598-023-44813-0
pmc: PMC10618203
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18764Informations de copyright
© 2023. The Author(s).
Références
Int J Epidemiol. 2014 Feb;43(1):69-77
pubmed: 24585853
Eur J Public Health. 2019 Feb 1;29(1):182-189
pubmed: 29878097
Epidemiol Health. 2021;43:e2021025
pubmed: 33872484
J Gerontol A Biol Sci Med Sci. 2011 Mar;66(3):301-11
pubmed: 21112963
BMC Health Serv Res. 2016 May 10;16:173
pubmed: 27160080
PLoS One. 2010 Dec 29;5(12):e15941
pubmed: 21209965
Cochrane Database Syst Rev. 2021 Jan 15;1:CD006560
pubmed: 33448337
BMJ. 2021 Aug 31;374:n1593
pubmed: 34465575
Ann Fam Med. 2005 May-Jun;3(3):223-8
pubmed: 15928225
J Gerontol A Biol Sci Med Sci. 2016 Feb;71(2):205-14
pubmed: 26419978
BMJ Med. 2022 Jul 27;1(1):e000247
pubmed: 36936594
Clin Hypertens. 2021 Mar 15;27(1):8
pubmed: 33715619
Korean J Intern Med. 2019 Jul;34(4):687-695
pubmed: 31272140
Lancet. 2018 Jul 7;392(10141):41-50
pubmed: 29961638
Age Ageing. 2022 Jul 1;51(7):
pubmed: 35871422
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS Med. 2021 Jun 17;18(6):e1003674
pubmed: 34138851
J Obes Metab Syndr. 2021 Jun 30;30(2):81-92
pubmed: 34045368
Lancet. 2012 Jul 7;380(9836):7-9
pubmed: 22579042
Int J Cardiol. 2014 Nov 15;177(1):202-8
pubmed: 25499379